Telomere biology: Cancer firewall or aging clock?
It has been a decade since the first surprising discovery that longer telomeres in humans are statistically associated with longer life expectancies. Since then, it has been firmly established that telomere shortening imposes an individual fitness cost in a number of mammalian species, including humans. But telomere shortening is easily avoided by application of telomerase, an enzyme which is coded into nearly every eukaryotic genome, but whose expression is suppressed most of the time. This raises the question how the sequestration of telomerase might have evolved. The predominant assumption is that in higher organisms, shortening telomeres provide a firewall against tumor growth. A more straightforward interpretation is that telomere attrition provides an aging clock, reliably programming lifespans. The latter hypothesis is routinely rejected by most biologists because the benefit of programmed lifespan applies only to the community, and in fact the individual pays a substantial fitness cost. There is a long-standing skepticism that the concept of fitness can be applied on a communal level, and of group selection in general. But the cancer hypothesis is problematic as well. Animal studies indicate that there is a net fitness cost in sequestration of telomerase, even when cancer risk is lowered. The hypothesis of protection against cancer has never been tested in animals that actually limit telomerase expression, but only in mice, whose lifespans are not telomerase-limited. And human medical evidence suggests a net aggravation of cancer risk from the sequestration of telomerase, because cells with short telomeres are at high risk of neoplastic transformation, and they also secrete cytokines that exacerbate inflammation globally. The aging clock hypothesis fits well with what is known about ancestral origins of telomerase sequestration, and the prejudices concerning group selection are without merit. If telomeres are an aging clock, then telomerase makes an attractive target for medical technologies that seek to expand the human life- and health-spans.
Key wordstelomere telomerase cancer programmed aging adaptive aging evolution
Unable to display preview. Download preview PDF.
- 14.Mitteldorf, J. (2006) Evol. Ecol. Res., 8, 561–574.Google Scholar
- 17.West, M. D. (2003) The Immortal Cell, Doubleday, New York.Google Scholar
- 39.Sahin, E., Colla, S., Liesa, M., Moslehi, J., Muller, F. L., Guo, M., Cooper, M., Kotton, D., Fabian, A. J., Walkey, C., Maser, R. S., Tonon, G., Foerster, F., Xiong, R., Wang, Y. A., Shukla, S. A., Jaskelioff, M., Martin, E. S., Heffernan, T. P., Protopopov, A., Ivanova, I., Mahoney, J. E., Kost-Alimova, M., Perry, S. R., Bronson, R., Liao, R., Mulligan, R., Shirihai, O. S., Chin, L., and DePinho, R. A. (2011) Nature, 470, 359–365.PubMedCrossRefGoogle Scholar
- 43.Shay, J. W. (2005) The Scientist, 19, 18–19.Google Scholar
- 44.Stearns, S. C. (1992) The Evolution of Life Histories, Oxford University Press, Oxford, New York.Google Scholar
- 51.Williams, G. (1966) Adaptation and Natural Selection, Princeton University Press, Princeton.Google Scholar
- 53.Sober, E., and Wilson, D. S. (1998) Unto Others: The Evolution and Psychology of Unselfish Behavior, Harvard University Press, Cambridge, MA.Google Scholar
- 54.Trubitsyn, A. (2006) Adv. Gerontol. (Russia), 19, 13–24.Google Scholar